Mankind Pharma's acquisition of Bharat Serums & Vaccines enhances its capabilities in biotechnology, positioning it as a leader in niche therapeutic areas within India's growing healthcare sector.

Information on the Target

Mankind Pharma, recognized for its commitment to affordable healthcare, is a leading player in the biotechnology sector of India. Founded in 1991 by Ramesh C. Juneja and Rajeev Juneja, Mankind Pharma commenced operations in 1995 with the vision of delivering high-quality medications at reasonable prices. Throughout its evolution, the company has emerged as India’s fourth-largest pharmaceutical firm, boasting a revenue of ₹10,335 crore for the financial year 2023-24. Initially concentrating on pharmaceuticals and consumer healthcare, Mankind Pharma has expanded into biotechnology to tackle pressing healthcare challenges.

Within biotechnology, Mankind Pharma has established a focus on developing biosimilars—biologically similar alternatives to complex biologic drugs. The company’s biotech division specializes in areas such as oncology, chronic inflammatory diseases, and metabolic disorders. Mankind Pharma's advanced R&D infrastructure supports its initiatives, employing methodologies like molecular biology, genetic engineering, cell culture, and more to facilitate the creation of effective and affordable biosimilars.

Industry Overview in the Target’s Specific Country

The biotechnology industry in India is witnessing remarkable growth, driven by increasing investment in research and development, advancements in technology, and a rising demand for biopharmaceuticals. The global biotechnology market is anticipated to experience